Jansens Pharmaceuticals Inc. is down nearly 20% this year, and it has struggled to regain the momentum it had when the stock started rising in early August.
The stock was up by nearly 5% during the first half of 2018, and that gain was cut off early last month when the company announced a plan to raise the price of its generic drug by 5%.
Janssen, which has a market value of about $14 billion, has been downgraded several times in the past year.
The company has been trading at about $1.20, down from about $2.20 a year ago.
That makes it the second-lowest-cost drug company after Pfizer, which also has an aggressive pricing strategy.
Jansen has also been losing money on its own generic drug business, which includes some generic versions of generic drugs that are approved for use in the United States.
As a result, Jansons stock has been trending down, with the company dropping more than 1% in the last month.
That’s the latest in a string of recent drops.
As of Monday, Jonsen’s market cap was $15.7 billion.
The drug company was trading at around $5.25 a share in January, down by more than 15% from the previous year.
At the end of June, it was trading between $4.50 and $5 a share.
At its current price, Jinsen’s shares are down more than 3%.
Jinsens stock was down more in the first quarter of 2019 than it was in the second quarter of 2018.
That year, Jainsen saw sales of its NexGen drug of $10 million.
The generic version of the drug was $12.2 million.
By the end, the generic version had a market share of more than half of Janss sales.
In 2018, Jensens lost about $4 billion on its Nexgen drug business.
It is also losing money by lowering prices on its generic drugs, which it has been trying to do for the past several years.
The new price increases could hurt Jansns profit.
Jainsens CEO and Chairman Richard Jansen said last month that the company will be taking a “proactive approach” in its price increases and expects to lose about $10 billion on the drug business by the end and is not looking to raise new debt or add new debt to its existing debt.
The latest price hikes are not likely to have a huge impact on Jansds stock price.
However, if the drug companies price hikes continue, investors could be watching for Jansson stock to drop more in 2018, potentially reversing its performance this year.
That could lead to further price declines for Jainsons stock, which was down about 6% last year.
In a recent interview with Bloomberg, Janson said the company was “not in the mood to be selling our shares,” which are down about $300 million since its initial public offering in May.
Janssen was able to maintain a strong share price in 2018 due to its aggressive pricing, which is also seen by investors.
In addition, Jansen was able at the time to negotiate favorable terms with drug companies for their generic drugs.
This is what allowed Jansners stock to grow during its short life as a drug company.